CR20150508A - Formulaciones veterinarias estables de combinación de lactonas macrocíclicas e imidazotiazoles - Google Patents

Formulaciones veterinarias estables de combinación de lactonas macrocíclicas e imidazotiazoles

Info

Publication number
CR20150508A
CR20150508A CR20150508A CR20150508A CR20150508A CR 20150508 A CR20150508 A CR 20150508A CR 20150508 A CR20150508 A CR 20150508A CR 20150508 A CR20150508 A CR 20150508A CR 20150508 A CR20150508 A CR 20150508A
Authority
CR
Costa Rica
Prior art keywords
combination
macrocyclic
imidazotiazoles
lactons
veterinary formulations
Prior art date
Application number
CR20150508A
Other languages
English (en)
Inventor
Rose Guy Francis De
Sachin Pundlik Kolhe
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50694063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150508(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CR20150508A publication Critical patent/CR20150508A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a composiciones estabilizadas que comprenden al menos una lactona macrocíclica, o un derivado de la misma, en combinación con levamisol, y un agente estabilizante de aminoazúcar, opcionalmente un agente antiparasitario adicional, y a un procedimiento para tratar o controlar una infección o infestación parasitaria en un animal mediante la administración de dicha composición.
CR20150508A 2013-04-12 2015-09-28 Formulaciones veterinarias estables de combinación de lactonas macrocíclicas e imidazotiazoles CR20150508A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361811138P 2013-04-12 2013-04-12
PCT/US2014/033599 WO2014169092A1 (en) 2013-04-12 2014-04-10 Composition of macrocyclic lactones, levamisole, an amino sugar and an additional antiparasitic agent

Publications (1)

Publication Number Publication Date
CR20150508A true CR20150508A (es) 2015-11-18

Family

ID=50694063

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150508A CR20150508A (es) 2013-04-12 2015-09-28 Formulaciones veterinarias estables de combinación de lactonas macrocíclicas e imidazotiazoles

Country Status (11)

Country Link
US (1) US10307405B2 (es)
EP (1) EP2983712B1 (es)
BR (1) BR112015025875B1 (es)
CL (1) CL2015002976A1 (es)
CR (1) CR20150508A (es)
ES (1) ES2846820T3 (es)
MX (1) MX364170B (es)
NZ (1) NZ712345A (es)
PE (1) PE20151726A1 (es)
PL (1) PL2983712T3 (es)
WO (1) WO2014169092A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102017010598A2 (pt) * 2017-05-19 2018-12-04 Flavio Alves Da Rocha composições veterinárias de liberação retardada para controle de ovos e larvas de helmintos nas fezes dos ruminantes, uso das composições, uso de antelmínticos com essa finalidade
EP3713413A1 (en) * 2017-11-23 2020-09-30 Ceva Sante Animale Composition for treating parasites infestations
NZ774180A (en) * 2018-09-05 2023-04-28 Zoetis Services Llc Palatable antiparasitic formulations
SI3815677T1 (sl) 2019-10-30 2023-12-29 Krka, D.D., Novo Mesto Stabilni veterinarski sestavek, ki obsega moksidektin in imidakloprid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4144352A (en) 1977-12-19 1979-03-13 Merck & Co., Inc. Milbemycin compounds as anthelmintic agents
EP0165900A3 (de) 1984-06-08 1986-05-28 Ciba-Geigy Ag Neue Lactone, Verfahren zu ihrer Herstellung und ihre Verwendung in der Schädlingsbekämpfung
US4916154A (en) 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
TWI285206B (en) 2000-04-27 2007-08-11 Sankyo Lifetech Company Ltd 13-substituted milbemycin derivatives, their preparation and their use against insects and other pests
US7348417B2 (en) 2003-08-07 2008-03-25 Wyeth Method of purifying moxidectin through crystallization
US7671034B2 (en) 2003-12-19 2010-03-02 Merial Limited Stabilized formulation of ivermectin feed premix with an extended shelf life
WO2006006021A2 (en) * 2004-06-28 2006-01-19 Glenmark Pharmaceuticals Limited Stabilized pharmaceutical compositions of preferably a statin
WO2006069580A1 (en) * 2004-12-30 2006-07-06 Cheminova A/S Oil-in-water formulation of avermectins
US7840123B2 (en) * 2007-06-21 2010-11-23 S.C. Johnson & Son, Inc. Diffusion device
CN101909450B (zh) 2007-11-26 2014-04-23 梅里亚有限公司 用于抗击寄生物的浇泼配制剂的溶剂系统
AU2009283313C1 (en) 2008-08-18 2014-07-31 Intervet Ineternational B.V. Anthelmintic compositions
UA108641C2 (uk) * 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
HUE028600T2 (en) 2010-05-12 2016-12-28 Merial Inc An injectable anticoagulant containing levamizole and macrocyclic lactone
EP3351546B1 (en) * 2011-12-02 2024-02-14 Boehringer Ingelheim Vetmedica GmbH Long-acting injectable moxidectin formulations

Also Published As

Publication number Publication date
CL2015002976A1 (es) 2016-05-06
US20160051524A1 (en) 2016-02-25
EP2983712A1 (en) 2016-02-17
US10307405B2 (en) 2019-06-04
MX364170B (es) 2019-04-15
PE20151726A1 (es) 2015-11-18
NZ712345A (en) 2016-04-29
BR112015025875A2 (pt) 2017-07-25
BR112015025875B1 (pt) 2021-06-29
ES2846820T3 (es) 2021-07-29
EP2983712B1 (en) 2020-11-25
WO2014169092A1 (en) 2014-10-16
MX2015014310A (es) 2016-02-16
PL2983712T3 (pl) 2021-05-31

Similar Documents

Publication Publication Date Title
NI201400842A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas.
BR112018075998A2 (pt) composições antifúngicas sinérgicas e métodos das mesmas
CL2014000601A1 (es) Composición tópica veterinaria que comprende al menos un agente activo derivado de isoxazolina; y uso de la composición para el tratamiento o prevención de una infestación o infección por parásitos en un animal.
CL2017002164A1 (es) Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
AR104212A1 (es) Formulaciones inyectables de liberación extendida que comprenden un agente activo de isoxazolina, métodos y usos de las mismas
AR098168A1 (es) Formulación estable de insulina glulisina
CR20150508A (es) Formulaciones veterinarias estables de combinación de lactonas macrocíclicas e imidazotiazoles
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CL2018003596A1 (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos. (divisional solicitud 201402831)
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
BR112017028468A2 (pt) formulação sólida oral, e método para preparar uma formulação sólida oral
BR112016029888A2 (pt) composições parasiticidas compreendendo derivados de indol, métodos e usos dos mesmos
BR112017020975A2 (pt) combinações antelmínticas e seus usos
EA201591583A1 (ru) Ветеринарная композиция для накожного применения
BR112013032567B1 (pt) composição aquosa antiparasitária veterinária solubilizada
BR112017014295A2 (pt) composição farmacêutica.
SV2016005348A (es) Mã‰todos para tratar infecciones
BR112016012235A8 (pt) composição veterinária de ação prolongada e uso de um pró-fármaco do tipo éster de cetoprofeno na preparação de medicamentos
CR20160591A (es) Metodos para tratar infecciones
EA201300351A1 (ru) Инъекционная ветеринарная композиция в виде раствора для борьбы с полиинвазиями животного и способ ее получения
BR112013012833A8 (pt) Composição farmacêautica e uso de um agente antimicrobiano de oxazolidinona